1. Search Result
Search Result
Results for "

urinary system

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125923

    Bacterial Infection Endocrinology
    Djenkolic acid is a sulfur-containing amino acid. Djenkolic acid can be isolated from the djenkol beans of the Southeast Asian plant Archidendron jiringa. Djenkolic acid de-inhibits the SO4 2- uptake system in Pseudomonas fluorescens. Djenkolic acid causes supersaturation of the urinary system with djenkolic acid crystals, leading to urinary tract obstruction and acute kidney injury .
    Djenkolic acid
  • HY-15935

    β-glucuronidase Fluorescent Dye Others
    X-Gluc Dicyclohexylamine is a dye reagent for the detection of β-glucuronidase, an enzyme produced by Escherichia coli. X-Gluc sodium can be used to detect E. coli contamination in food, water and the urinary tract. X-Gluc sodium is also widely used in molecular biology experiments to label and detect the expression of target genes (GUS reporter system) .
    X-Gluc Dicyclohexylamine
  • HY-15574
    Piboserod
    3 Publications Verification

    SB-207266

    5-HT Receptor Cardiovascular Disease
    Piboserod is an orally available selective antagonist of the 5-HT4 receptor, with a Ki value of approximately 0.1 nM for human 5-HT4 receptors. Piboserod can competitively bind to the 5-HT4 receptor and block the activation of the 5-HT4 receptor. Piboserod can inhibit the enhancing effect of 5-HT on the nerve-mediated contraction response of the human bladder detrusor muscle. Piboserod is mainly used in the research of urinary system diseases (such as overactive bladder) and cardiovascular diseases (such as chronic heart failure) .
    Piboserod
  • HY-125923R

    Reference Standards Bacterial Infection Endocrinology
    Djenkolic acid (Standard) is the analytical standard of Djenkolic acid (HY-125923). This product is intended for research and analytical applications. Djenkolic acid is a sulfur-containing amino acid. Djenkolic acid can be isolated from the djenkol beans of the Southeast Asian plant Archidendron jiringa. Djenkolic acid de-inhibits the SO4 2- uptake system in Pseudomonas fluorescens. Djenkolic acid causes supersaturation of the urinary system with djenkolic acid crystals, leading to urinary tract obstruction and acute kidney injury .
    Djenkolic acid (Standard)
  • HY-174808

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer .
    SC691
  • HY-14790

    (S,S)-Reboxetine

    Adrenergic Receptor Neurological Disease
    Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .
    Esreboxetine
  • HY-B1435A

    Thymoxamine

    Adrenergic Receptor Neurological Disease
    Moxisylyte (Thymoxamine) is an alpha 1-selective antagonist with activity that improves bladder emptying. Moxisylyte is used to suppress urinary difficulties in patients with multiple system atrophy (MSA) by blocking alpha 1-adrenergic receptors to reduce the amount of residual urine after urination. Moxisylyte is also used to suppress erectile dysfunction and can improve blood circulation problems caused by Raynaud's syndrome in the short term. In addition, Moxisylyte can be applied topically to the eye to reverse the mydriasis caused by phenylephrine and other sympathetic stimulants .
    Moxisylyte
  • HY-15574R

    5-HT Receptor Cardiovascular Disease
    Piboserod (Standard) is the analytical standard of Piboserod. This product is intended for research and analytical applications. Piboserod is an orally available selective antagonist of the 5-HT4 receptor, with a Ki value of approximately 0.1 nM for human 5-HT4 receptors. Piboserod can competitively bind to the 5-HT4 receptor and block the activation of the 5-HT4 receptor. Piboserod can inhibit the enhancing effect of 5-HT on the nerve-mediated contraction response of the human bladder detrusor muscle. Piboserod is mainly used in the research of urinary system diseases (such as overactive bladder) and cardiovascular diseases (such as chronic heart failure) .
    Piboserod (Standard)
  • HY-D1056B2

    LPS, from bacterial (Proteus mirabilis)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from Proteus mirabilis
  • HY-137055

    Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: